1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Molecular signature of patients with pre-treated urothelial carcinoma (UC) achieving extreme responses to pazopanib (PZP) salvage therapy
    Meeting Abstract

    Pinciroli, P.; Iyer, G.; Won, H. H.; Canevari, S.; Colecchia, M.; De Braud, F. G.; Daidone, M. G.; Giannatempo, P.; Raggi, D.; Pennati, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Is next generation sequencing (NGS) ready for routine clinical practice in gliomas? Results of a prospective study utilizing the MSK-IMPACT assay
    Meeting Abstract

    Omuro, A. M. P.; Zehir, A.; Cheng, D. T.; Berger, M. F.; Hyman, D. M.; Solit, D. B.; Baselga, J.; Ladanyi, M.; Arcila, M. E.; Hameed, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Efficacy and safety of endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors (TKI) after programmed cell death 1 (PD-1) inhibitor treatment in patients with metastatic clear cell renal cell carcinoma (mccRCC)
    Meeting Abstract

    Nadal, R.; Amin, A.; Geynisman, D. M.; Voss, M. H.; Weinstock, M.; Doyle, J.; Zhang, Z.; Viudez, A.; Plimack, E. R.; McDermott, D. F.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Randomized phase II, three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Motzer, R.; Hutson, T.; Glen, H.; Michaelson, D.; Molina, A. M.; Eisen, T.; Jassem, J.; Zolnierek, J.; Maroto, P.; Mellado, B.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • RECORD-4: A multicenter, phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Motzer, R.; Alyasova, A.; Ye, D. W.; Karpenko, A.; Li, H. Z.; Alekseev, B. Y.; Xie, L. P.; Kurteva, G. P.; Kowalyszyn, R. D.; Neron, Y.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Efficacy analysis of a phase III study of androgen deprivation therapy (ADT) +/- docetaxel (D) for men with biochemical relapse (BCR) after prostatectomy
    Meeting Abstract

    Morris, M. J.; Hilden, P.; Gleave, M. E.; Armstrong, A. J.; Carducci, M. A.; Saad, F.; Dayan, E. S.; Filipenko, J.; Acosta, I.; Heller, G.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Effects of radium-223 dichloride (Ra-223) with docetaxel (D) vs D on prostate-specific antigen (PSA) and bone alkaline phosphatase (bALP) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases (mets): A phase 1/2a clinical trial
    Meeting Abstract

    Morris, M. J.; Higano, C. S.; Scher, H. I.; Sweeney, C.; Antonarakis, E. S.; Shevrin, D. H.; Ryan, C. J.; Loriot, Y.; Fizazi, K.; Pandit-Taskar, N.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • A phase I study of buparlisib (BKM120) with bevacizumab (BEV) in patients (pts) with metastatic renal cell carcinoma (mRCC) progressing on prior vascular endothelial growth factor (VEGF) therapies
    Meeting Abstract

    McKay, R. R.; Werner, L.; Harshman, L. C.; Bellmunt, J.; Sweeney, C.; Rosenberg, J. E.; VanAllen, E.; Walsh, M. K.; Vaishampayan, U. N.; McDermott, D. F.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Analysis of real world treatment compliance in a cohort of 2,395 patients with metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Margolis, J.; Princic, N.; Doan, J.; Lenhart, G.; Motzer, R.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Early CTC decline as a biomarker of response to treatment in castration-resistant prostate cancer (CRPC): Analysis of the COU-AA-301 and IMMC38 trials
    Meeting Abstract

    Lorente, D.; Olmos, D.; Mateo, J.; Bianchini, D.; Seed, G.; Flohr, P.; Crespo, M.; Figueiredo, I.; Miranda, S.; Baeten, K.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save